Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30(-) Tumors

Hombach, Andreas A. and Rappl, Gunter and Abken, Hinrich (2019) Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30(-) Tumors. MOLECULAR THERAPY, 27 (10). pp. 1825-1835. ISSN 1525-0016, 1525-0024

Full text not available from this repository. (Request a copy)

Abstract

Chimeric antigen receptor (CAR)-engineered T cells are efficacious in controlling advanced leukemia and lymphoma, however, they fail in the treatment of solid cancer, which is thought to be due to insufficient T cell activation. We revealed that the immune response of CAR T cells with specificity for carcinoembryonic antigen (CEA) was more efficacious against CEA(+) cancer cells when simultaneously incubated with an anti-CD30 immunotoxin or anti-CD30 CAR T cells, although the targeted cancer cells lack CD30. The same effect was achieved when the anti-CD30 single-chain variable fragment (scFv) was integrated into the extracellular domain of the anti-CEA CAR. Improvement in T cell activation was due to interfering with the T cell CD30-CD30L interaction by the antagonistic anti-CD30 scFv HRS3; an agonistic anti-CD30 scFv or targeting the high-affinity interleukin-2 (IL-2) receptor was not effective. T cells with the anti-CD30/CEA CAR showed superior immunity against established CEA(+) CD30(-) tumors in a mouse model. The concept is broadly applicable since anti-CD30/TAG72 CAR T cells also showed improved elimination of TAG72(+) CD30(-) cancer cells. Taken together, targeting CD30 on CAR T cells by the HRS3 scFv within the anti-tumor CAR improves the redirected immune response against solid tumors.

Item Type: Article
Uncontrolled Keywords: ANTIIDIOTYPE VACCINE; HODGKINS LYMPHOMA; SPACER DOMAIN; B-CELL; EXPRESSION; RECEPTOR; ACTIVATION; IL-4; PROLIFERATION; CONSTRUCTION;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Regensburger Centrum für Interventionelle Immunologie (RCI)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 25 Mar 2020 13:43
Last Modified: 25 Mar 2020 13:43
URI: https://pred.uni-regensburg.de/id/eprint/26031

Actions (login required)

View Item View Item